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Abstract 
Introduction 
Studies suggest that the bioactive compounds contained within the rhizome of ginger (Zingiber 
officinale) could exert a beneficial effect on the symptoms of several chronic conditions (e.g. 
diabetes, arthritis) and in the reduction of nausea. However, it is unknown if ginger supplements 
and food products contain sufficient quantities of the necessary active ingredients to achieve a 
therapeutic effect.  
This study analyzed twenty commercially available ginger products including ginger dietary 
supplements, ginger spices (ground dried ginger), and ginger-containing drinks and food 
products and determined the concentration of [6]-, [8]- and [10]- gingerol and [6]- and [10]-
shogaol.  
Methods 
The samples were extracted prior to separation by Reversed Phase-High Performance Liquid 
Chromatography (RP-HPLC) and detected by ultraviolet (UV) spectrophotometry. 
Results 
Considerable variation between individual items within each food type was observed. Per gram, 
ginger supplements, particularly the standardized extracts, contained the greatest concentration 
of measured compounds (10.08±7.92 mg, mean±standard deviation), while the concentration of 
compounds within spices (9.29±6.73 mg), beverages (1.77±1.06 mg), confectionery (0.43±0.32 
mg), and teas (0.13±0.00 mg) was considerably lower. When the concentration of compounds 
were measured per standardized serve, four ginger confectionery and beverage products 
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contained total gingerol and shogaol concentrations that were similar to the analyzed dietary 
supplement. 
Conclusion 
Of the twenty commercially available ginger products examined, those with the highest content 
of active, antiemetic constituents were the standardized ginger extracts and supplements although 
ginger spices also showed high levels of active constituents per serve.  In addition, standard 
deviation reveals a large variation within each product type. 
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1.0 Introduction 
The rhizome of ginger (Zingiber officinale) contains many bioactive compounds. The 
gingerol class of compounds is the primary bioactive agent within the non-volatile, pungent 
component of ginger. Shogaols are the degradation product of gingerols. These are present in 
low concentrations in fresh ginger but increase when gingerols are exposed to heat, acid or other 
conditions which allow the alkene to form (an elimination product) (Bhattarai et al., 2001). The 
shogaols and gingerols are differentiated by the presence of either an aliphatic hydroxyl group, 
beta to the carbonyl (gingerols) or elimination of the hydroxyl group to form a double bond 
(shogaols) on the alpha carbon to the aliphatic carbonyl.  
These compounds have been studied in clinical and pre-clinical studies for their effect on 
several chronic conditions such as diabetes and arthritis (Altman and Marcussen, 2001; 
Khandouzi et al., 2015; Marx et al., 2013). The potentially beneficial effect of ginger on nausea 
has also been an area of significant research interest. A growing body of clinical trials has 
provided preliminary support for its use in multiple types of nausea such as motion sickness, 
morning sickness and chemotherapy-induced nausea and vomiting (Marx, W. et al., 2015; 
Thomson et al., 2014; Viljoen et al., 2014). Studies that have investigated the antioxidant, anti-
inflammatory, and chemo-preventive effect of individual compounds contained in ginger have 
reported different levels of activity depending on the chain length and presence of an alpha, beta-
unsaturated ketone group. For example, when several gingerol and shogaol compounds were 
compared, Dugasini et al. reported [6]-shogaol to be the most potent inhibitor of inflammation 
and reactive oxygen species production and [10]-gingerol to be the most potent gingerol. 
(Dugasani et al., 2010)  
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Because of purported medicinal effects, ginger products are often used by the general 
population as complementary medicines and are sometimes recommended by healthcare 
professionals as adjuvants to standard therapy (Forster et al., 2006; Holst et al., 2009; Molassiotis 
et al., 2011). However, there are currently few studies that have investigated the concentration of 
active compounds in a wide-variety of commercially available products, and thereby providing a 
reliable guide to appropriate use of these products (Schwertner et al., 2006; Schwertner and Rios, 
2007). Due to the increasing public use of complementary treatments such as dietary 
supplements, information regarding the potency of available ginger preparations will also be of 
interest to healthcare professionals seeking these products for their adjuvant medicinal properties 
to determine their potential to produce side effects and interactions. Due to the differing 
biological activity of the gingerol and shogaol compounds, it is also prudent to measure the 
concentration of each of these individual compounds within commonly consumed ginger 
products. 
The aim of this study was to determine the concentration of the primary bioactive 
compounds within an expanded range of commercially available ginger products, including 
dietary supplements and ginger-containing drinks and food products using Reverse Phase-High 
Performance Liquid Chromatography (RP-HPLC). Using the results of this analysis, the clinical 
and research implications of the therapeutic use of ginger products will be discussed. 
2.0 Methods 
2.1 Chemicals and Materials 
HPLC-grade water, methanol, ethyl acetate, and acetonitrile were purchased from ThermoFisher 
(Massachusetts, USA) and Sigma Aldrich (Missouri, USA). [6]-, [8]- and [10]- gingerol and [6]- 
5 
 
and [10]-shogaol standards were purchased from Chromadex (Irvine, CA, U.S.A). Ginger 
products were purchased from one local supermarket (Gold Coast, Australia) and one online 
store (based in New Zealand) in April, 2014. In addition, one supplement was supplied by the 
respective manufacturer for use in this study. In total, 20 products were purchased, including 
dietary supplements, beverages, spices (ground ginger), teas, and confectionery.  
2.2 Sample preparation 
Due to the variety of types of ginger products analyzed, two extraction protocols were required. 
All samples were prepared in triplicate. Percentage yield was determined by conducting each 
extraction protocol with a 0.08 mg/mL standard mix.  
2.3 Ethyl acetate extraction  
In order to analyze the ginger supplements, biscuit, and spices, ethyl acetate (10mL) was added 
to 500mg samples of spices, pierced supplements or crushed biscuit. 
Samples were vortexed then sonicated for 30 minutes using a CamLab TransSonic T310 
sonicator. Samples were centrifuged (20 minutes at 2500rpm and 25 degrees Celsius) using a 
Beckman Coulter Allegra X-15R centrifuge. The supernatant was subjected to second pass 
extraction using an additional ethyl acetate (10 mL). The supernatants of both extractions from 
each product were combined and evaporated to dryness. The samples were reconstituted in 
methanol (1.5mL) and stored at 4ºC. 
Serving sizes for the supplements and biscuit were in accordance with suggested serving sizes by 
the manufacturer. The serving size for the spices was set at 0.2 gram. 
2.4 Liquid/liquid extraction 
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Beverage samples (50mL, degassed) and confectionery samples (500mg) were diluted in HPLC 
water (15mL). For the tea products, three tea bags were infused in HPLC-grade water (50mL, 
room temperature) for three minutes. All samples were left overnight and then extracted in ethyl 
acetate (10mL). A second pass extraction was conducted. The supernatants of both extractions 
from each product were combined and evaporated to dryness. The samples were reconstituted in 
methanol (1.5mL) and stored at 4ºC.  
The serving size of the beverages was set at 250mL and confectionery serving size was defined 
as 5g, as this was found to be the approximate weight of a single piece of confectionery.  
2.5 Standard preparation 
Stock solutions (10mL) of each standard were prepared from the 5mg material supplied by the 
manufacturer Chromadex (Irvine, CA, U.S.A). A dilution series of the standard mix were 
prepared as needed between 0.50 ug/mL to 200 ug/mL. Working standards were prepared in the 
range of 0.0005 to 0.2 mg/mL and stored at 4ºC.  
2.6 HPLC analysis  
Ginger samples were separated on a Waters Alliance e-2695 Separations System RP-HPLC and 
detected with a 2489 Dual-Beam UV detector. A 150x4.6mm C-18 reversed phase column (Luna 
C18 5µM; Phenomenex, USA) was fitted with a guard column. 
The mobile phase consisted of HPLC-grade water (A) and acetonitrile (B) at starting conditions 
of 90% A. Analytical conditions included an injection volume of 10µL, flow rate of 1.5mL per 
minute and a column temperature of 27ºC. A binary gradient elution system was applied as 
follows: 0.0–1.85 min, 10–50% B; 1.86–7.88 min, 55% B; 7.89–11.59 min, 66% B; 12–17.6 
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min, 100% B. 17.61-25 min 10% B. The UV absorbance was measured at 205nm. Peak 
identification was based on the retention time of the standards. 
3.0 Results 
Calibration curves for [6]-gingerol, [6]-shogaol, [8]-gingerol, [10]-shogaol, and [10]-gingerol 
were linear between 0.5 to 200.0 ng/mL (correlation coefficient for each compound were 
≥0.9992).  
Sample chromatograms for each of the product categories are set out in Supplemental 
Information 1.  
As expected the elution order correlates with the lipophilicity of each compound, that is, [6]-
gingerol, [8]-gingerol, [6]-shogaol, [10]-gingerol, [10]-shogaol. 
The limit of detection (LoD) was determined using the standard deviation of each component 
calibration curve and slope. The LoD was calculated as 3.3 times the ratio of standard deviation 
to slope for each component while the limit of quantitation (LoQ) was calculated as 10 x the 
ratio of standard deviation to slope for each component (Table 1).  
The mean concentration of [6]-gingerol, [6]-shogaol, [8]-gingerol, [10]-gingerol and [10]-
shogaol of all ginger products are tabulated per gram (Table 2) and per serving (Table 3) after 
they had been adjusted by the percentage yield as determined by the validation protocol. 
In all samples, [6]-gingerol was consistently detected in the highest concentration when 
compared to all other compounds investigated while [8]-gingerol and [10]-shogaol were found in 
the lowest concentration. In descending order, the total concentration of each compound from all 
analyzed products was [6]-gingerol (67.42mg), [6]-shogaol (20.18mg), [10]-gingerol (15.52mg), 
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[10]-shogaol (7.78mg), [8]-gingerol (7.58mg). This order of [6]-gingerol, [6]-shogaol, and [10]-
gingerol remained consistent for each product; however, some products contained slightly higher 
concentrations of [8]-gingerol than [10]-shogaol.  
Figure 1 Total mean gingerol and shogaol content of ginger products per gram by group 
The concentration of analyzed compounds, particularly within the beverages, varied considerably 
(Figure 1). When compared per gram, with one exception, ginger supplements (particularly 
those that were made from standardized extracts) contained the largest concentration of analyzed 
compounds when compared to all other ginger products. Ginger spices also tended to contain a 
large concentration of compounds per gram while the ginger biscuit contained the lowest 
amount. When the concentration of each product was compared per serve, standardized extracts 
still contained some of the largest concentration of compounds (Figure 2). Products from other 
categories (i.e. beverages and confectionery) contained concentrations of compounds similar to 
the standardized extracts.  
Figure 2 Total mean gingerol and shogaol content of ginger products per serve by group 
4.0 Discussion 
In this study, the concentration of the principle gingerol and shogaol compounds was analyzed in 
20 commercially available ginger products. The results of the current study expand on previous 
studies by increasing the range and type of products analyzed and by including an additional 
compound, [10]-shogaol, in the analysis. [10]-shogaol has not been extensively studied; 
however, in vitro research suggests that it exerts anti-inflammatory properties and might aid 
wound healing (Chen et al., 2012; van Breemen et al., 2011). Hence, quantification of this 
compound in various ginger products can assist in future research studies. 
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In line with previous studies, the amount of each compound was relatively consistent across all 
products with [6]-gingerol and its degradation product, [6]-shogaol detected in the greatest 
concentrations and [8]-gingerol and [10]-shogaol in the smallest concentrations (Schwertner and 
Rios, 2007; Shao et al., 2010). The greater concentration of [6]-gingerol is to be expected as [6]-
gingerol is the primary non-volatile pungent compound within the oleoresin of ginger.  
This analysis also demonstrated a substantial variation in bioactive compounds between 
products. Per gram, ginger supplements, particularly the standardized extracts, contained the 
greatest concentration of measured compounds, while the concentration of compounds within 
other product categories varied considerably. These findings are similar to the results of 
previously published analyses by other groups (Schwertner et al., 2006; Schwertner and Rios, 
2007; Shao et al., 2010).  
The low concentration of active compounds contained in the analyzed tea products is in contrast 
to previous research which reported tea products to be similar in concentration to some dietary 
supplements and spices (Schwertner and Rios, 2007; Shao et al., 2010). However, we chose to 
measure the concentrations of active ingredients in brewed tea in order to better reflect the 
amount of active ingredients likely to be ingested with tea consumption, as opposed to previous 
studies which measured the concentration of active ingredients in the tea bag before brewing. 
Because gingerol compounds transform into shogaols when exposed to heat, our method 
provides a more accurate determination of the active ingredients consumed under normal 
conditions.  
Previous studies reported that the total concentration of active components within commercially 
available dietary supplements varied considerably from the manufacturers’ claims (Harkey et al., 
2001; Heptinstall et al., 1992). In contrast, we found that the concentrations of gingerols and 
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shogaols in the three standardized extracts included in this analysis were consistent with those 
published by the manufacturers. 
When analyzed in terms of the approximate concentration that would be consumed in one 
recommended serve of each product, there were dietary supplements as well as some 
confectionery and beverage products, that contained large concentrations of the analyzed 
compounds. Ginger ales and confectionery are often recommended by health professionals to 
treat nausea. Currently, the smallest effective dose of ginger as well as the optimal form of 
ginger has not been elucidated and is an area that requires continued research to inform clinical 
practice. However, these results demonstrate that it is feasible to achieve an intake of the 
principle active compounds of ginger by consuming certain commercially available food 
products that is comparable to most dietary supplements analyzed in this study as well as 
effective doses used in previous clinical trials. For example, a large RCT (N=576) reported that 
two dosages of a standardized ginger extract, 0.5 and 1g/day, were effective in reducing 
chemotherapy-induced nausea and vomiting (Ryan et al., 2012). The effective daily dose of 
gingerol and shogaol for each dosage was 17mg and 34mg, respectively. In our analysis, four 
confectionery and beverage products contained a total gingerol and shogaol concentration similar 
to the dosage used in previous studies and the dietary supplements included in the current 
analysis (Ryan et al., 2012). Therefore, these results also suggest that it is indeed feasible to 
attain equivalent amounts of gingerol and shogaols used in previous clinical trials via dietary 
intake (Ryan et al., 2012). This demonstrates the need for the consumption of ginger products to 
be monitored during future clinical trials investigating ginger because the consumption of 
additional ginger products is likely to influence the effective total intake of ginger compounds. 
Furthermore, previous studies have demonstrated a potential ceiling effect with higher doses (2g) 
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of ginger supplementation resulting in less or no control of symptoms compared to lower doses 
(Marx et al., 2013). Thus, the consumption of additional ginger products could potentially 
increase the total consumption of active compounds in excess of a therapeutic dosage.  
In addition, as previously noted by our group as well as other authors, the lack of analysis of 
ginger preparations and the lack of standardized extracts used in clinical trials could be 
responsible for the sometimes conflicting results reported due to the variability in active 
compounds (Marx, Wolfgang et al., 2015; Marx et al., 2013; Schwertner and Rios, 2007). The 
results of this study support this concern as there was a large difference in the detected 
concentration of each investigated product, including the ginger supplements. Hence, the 
measurement of the concentration of the active compounds within ginger products as well as the 
use of standardized extracts is indicated in future trials. 
It should be noted that ginger contains a wide variety of bioactive compounds that have 
potentially beneficial properties (Chrubasik et al., 2005). Therefore, while this study was able to 
determine the concentration of an expanded range of these principle compounds compared to 
previous studies, other potentially important ginger compounds were not able to be analyzed due 
to the lack of commercial standards. Investigation of the concentrations of other compounds such 
as zingibain and dehydroshogaols in commercial products is recommended in future studies as 
these compounds have also demonstrated biological activity relevant to chronic conditions 
(Chrubasik et al., 2005). A second limitation of this study is that some of the samples used were 
purchased commercially from nearby stores. The concentration of compounds could have been 
influenced by factors such as storage conditions; therefore, the results of this analysis might not 
be representative of the product when stored in different conditions. There is also the possibility 
that there was a variation in the concentration of analyzed compounds between different batches 
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of the same product, particularly if different batches are sourced from multiple locations. This 
study analyzed a single sample of each product and so future trials may benefit from analyzing 
multiple batches of the same product. Finally, due to the use of ethyl-acetate to extract the active 
compounds, our study provides limited data on the bioaccessability of the active compounds. 
However, rather than to compare the bioaccessibilty of target analytes, the current study was 
designed to measure and compare the total composition of gingerols and shogaols in the included 
products. The bioaccessibilty of these compounds is an area of necessary research and future 
studies that resemble the human digestive process (e.g. by using an aqueous extraction) are 
required to improve the current literature.  
In summary, using an expanded range of commercial ginger products, the inclusion of an 
additional active compound, and a protocol designed to reflect the concentration of active 
compounds likely to be consumed, the results and discussion of this study provide novel clinical 
and research recommendations regarding the therapeutic use of ginger products. 
5.0 Conclusion 
An analysis of 20 commercially available ginger products demonstrated wide variation in the 
total amount of gingerols and shogaols within different ginger products, with standardized ginger 
extracts and spices containing the largest concentration of compounds. Biscuits and teas 
contained the least concentrations of the relevant compounds. When calculated by serving, 
certain beverages and confectionery contained similar or greater concentrations of the analyzed 
compounds to the ginger supplements; hence, future clinical trials investigating ginger 
formulations should ensure that the consumption of other ginger products is monitored so as to 
not confound the study results. In addition, the inconsistent concentration of active compounds 
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within ginger supplements demonstrates the need for standardized extracts and the use of RP-
HPLC in clinical trials to ensure sufficiently potent interventions. 
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TABLES 
Table 1. Correlation coefficient and Limits of Detection/Quantitation for each component 
  
Ginger component Coefficient of determination 
(R2) 
Limit of 
Detection (LoD) 
Limit of 
Quantitation 
(LoQ) 
[6]-Gingerol 0.9995 7.05x10-3 ug/mL 21.4 ug/mL 
[8]-Gingerol 0.9996 6.77x10-3 ug/mL 20.5 ug/mL 
[10]-Gingerol 0.9994 8.68 x10-3 ug/mL 26.2 ug/mL 
[6]-Shogaol 0.9993 7.71x10-3 ug/mL 23.4 ug/mL 
[10]-Shogaol 0.9992 8.47 x 10-3 ug/mL 25.7 ug/mL 
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Table 2. Mean ± standard deviation concentration in analyzed products per gram.  
Supplements  Total 
(mg/caps
ule) 
6G 
(mg/L)  
8G 
(mg/L)  
10G 
(mg/L) 
6S 
(mg/L)  
10S 
(mg/L)  
Nature’s Own Travel 
Well 1000 
0.66 0.47±0.02 0.00±0.00 0.02±0.01 0.14±0.01 0.03±0.00 
Lifestream Ginger 
capsules 
7.44 4.59±0.73 0.35±0.20 0.88±0.15 1.22±0.21 0.38±0.07 
Nature's Sunshine 
Ginger  
7.02 2.32±0.03 0.43±0.02 0.89±0.02 2.20±0.05 1.17±0.04 
BlueBonnet Ginger root 
extract 
23.57 12.76±0.0
1 
1.74±0.01 2.89±0.01 4.63±0.01 1.55±0.01 
Blackmores Travel Calm 
Ginger 
7.36 4.35±0.15 0.61±0.02 1.00±0.04 1.03±0.03 0.37±0.02 
Helsinn Integrative Care 
Ginpax 40mg soft gel 
capsule 
14.46 11.08±1.4
9 
0.14±0.04 2.77±0.44 0.02±0.01 0.44±0.05 
Spices  Total 
(mg/g) 
6G 
(mg/L)  
8G 
(mg/L)  
10G 
(mg/L) 
6S 
(mg/L)  
10S 
(mg/L)  
Woolworth's Ginger 
Spice Powder 
13.42 5.64±0.02 1.34±0.00 3.11±0 2.13±0.00 1.19±0.0 
Coles Ginger Spice 
Powder 
12.93 5.50±0.17 1.21±0.04 3.12±0.1 2.01±0.0 1.09±0.04 
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Hertz Ginger Spice 
Powder 
1.53 0.88±0.13 0.14±0.02 0.22±0 0.21±0.03 0.08±0.01 
Beverages  Total 
(mg/L) 
6G 
(mg/L)  
8G 
(mg/L)  
10G 
(mg/L) 
6S 
(mg/L)  
10S 
(mg/L)  
Coles Dry Ginger Ale 1.94 1.58±0.66 0.04±0 0.18±0.1 0.10±0.08 0.04±0.04 
Bundaberg Diet Ginger 
Beer 
0.61 0.53±0.02 0.02±0.00 0.00±0 0.05±0.0 0.00±0.0 
Saxby Dry Ginger Beer 2.20 1.85±0.21 0.04±0.03 0.14±0 0.11±0.01 0.06±0.01 
Cascade Ginger Beer 3.23 2.86±0.41 0.07±0.04 0.13±0 0.12±0.01 0.04±0.0 
Tiger Ginger Beer 0.86 0.50±0.66 0.04±0.03 0.18±0.1 0.10±0.08 0.04±0.04 
Confectionary  Total 
(mg/L) 
6G 
(mg/L)  
8G 
(mg/L)  
10G 
(mg/L) 
6S 
(mg/L)  
10S 
(mg/L)  
Gin Gins Candies 0.68 0.60±0.05 0.02±0.00 0.02±0 0.03±0.0 0.01±0.0 
Buderim Crystallised 
Ginger 
0.70 0.63±0.06 0.00±0.00 0.02±0 0.04±0.0 0.00±0.0 
Buderim Ginger bears 0.34 0.32±0.02 0.01±0.00 0.00±0 0.01±0.00 0.00±0 
Arnotts GingerNut 
Biscuits 
0.02 0.02±0.00 0.00±0.00 0.00±0 0.00±0 0.00±0 
Teas Total 
(mg/L) 
6G 
(mg/L)  
8G 
(mg/L)  
10G 
(mg/L) 
6S 
(mg/L)  
10S 
(mg/L)  
Twinings Ginger & 
Lemon Tea 
0.13 0.13±0.00 0.00±0.00 0.00±0 0.00±0 0.00±0 
Nerada Ginger & Lemon 
Tea 
0.13 0.13±0.01 0.00±0.00 0.00±0 0.00±0 0.00±0 
*6G=[6]-gingerol, 8G =[8]-gingerol, 6S=[6]-shogaol, 10G=[10]-gingerol, 10S=[10]-shogaol.   
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Table 3. Mean ± standard deviation concentration of [6]-gingerol, [6]-shogaol, [8]-gingerol, 
[10]-gingerol and [10]-shogaol in analyzed products per serving size.  
Supplements  Estimate
d serving 
size (g)  
Total 
(Per 
serving
) 
6G 
(Per 
serving) 
8G 
(Per 
serving) 
10G 
(Per 
serving) 
6S 
(Per 
serving) 
10S 
(Per 
serving) 
Nature’s Own 
Travel Well 1000 
0.85g 1.68 1.19±0.05 0.00±0 0.36±0.0
3 
0.05±0.02
6 
0.08±0 
Lifestream 
Ginger capsules 
0.66g 18.92 11.68±1.8
6 
0.90±0.5
1 
3.11±0.5
3 
2.25±0.38
1 
0.98±0.1
7 
Nature's 
Sunshine Ginger  
0.60g 12.58 4.16±0.05 0.76±0.0
3 
3.95±0.1 1.60±0.03
7 
2.10±0.0
7 
BlueBonnet 
Ginger root 
extract 
0.52g 36.43 19.72±0.0
2 
2.69±0.0
2 
7.15±0.0
2 
4.46±0.01
6 
2.39±0.0
2 
Blackmores 
Travel Calm 
Ginger 
0.51g 11.16 6.60±0.22 0.92±0.0
3 
1.56±0.0
5 
1.51±0.05
5 
0.57±0.0
3 
Helsinn 
Integrative Care 
Ginpax 40mg 
soft gel capsule 
0.24g 21.68 16.63±2.2
3 
0.21±0.0
5 
0.03±0.0
2 
4.16±0.66
5 
0.65±0.0
8 
Spices   Total 6G 8G 10G 6S 10S 
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(Per 
serving
) 
(Per 
serving) 
(Per 
serving) 
(Per 
serving) 
(Per 
serving) 
(Per 
serving) 
Woolworth's 
Ginger Spice 
Powder 
0.212g 8.72 3.66±0.01 0.87±0.0
0 
2.02±0.0
0 
1.38±0.00 0.77±0.0
0 
Coles Ginger 
Spice Powder 
0.212g 8.40 3.57±0.11 0.79±0.0
3 
2.03±0.0
6 
1.31±0.04 0.71±0.0
2 
Hertz Ginger 
Spice Powder 
0.212g 0.99 0.57±0.08 0.09±0.0
1 
0.15±0.0
2 
0.14±0.02 0.05±0.0
1 
Beverages  
  
  
  
Total 
(Per 
serving
) 
6G 
(Per 
serving) 
8G 
(Per 
serving) 
10G 
(Per 
serving) 
6S 
(Per 
serving) 
10S 
(Per 
serving) 
Coles Dry Ginger 
Ale 
250mL 4.56 3.98±0.13 0.18±0.0
1 
0.03±0 0.35±0.01
6 
0.01±0 
Bundaberg Diet 
Ginger Beer 
250mL 16.50 13.89±1.6
1 
0.31±0.2 1.02±0.1
2 
0.80±0.08
3 
0.47±0.0
6 
Saxby Dry 
Ginger Beer 
250mL 24.23 21.49±3.0
5 
0.51±0.3
1 
1.01±0.1
3 
0.90±0.07
7 
0.32±0.0
3 
Cascade Ginger 
Beer 
250mL 6.48 3.76±4.98 0.30±0.2
4 
1.32±0.8
9 
0.77±0.61 0.33±0.2
8 
Tiger Ginger 
Beer 
250mL 5.09 4.48±0.41 0.14±0.0
2 
0.18±0.0
2 
0.22±0.03
7 
0.07±0.0
2 
Confectionary   Total 6G 8G 10G 6S 10S 
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    (Per 
serving
) 
(Per 
serving) 
(Per 
serving) 
(Per 
serving) 
(Per 
serving) 
(Per 
serving) 
Gin Gins Candies 12g 25.12 22.85±2.2
0 
0.15±0.0
3 
0.65±0.0
7 
1.40±0.14
1 
0.08±0.0
2 
Buderim 
Crystallised 
Ginger 
25g 5.16 4.74±0.25 0.16±0.0
1 
0.00±0.0
0 
0.19±0.00
8 
0.06±0 
Buderim Ginger 
bears 
48g 11.88 10.38±0.8
4 
0.58±0.0
2 
0.45±0.0
2 
0.43±0.02
5 
0.04±0 
Arnotts 
GingerNut 
Biscuits 
1 biscuit 2.14 1.28±0.03 0.14±0.0
0 
0.29±0.0
0 
0.24±0 0.19±0.0
3 
Teas     Total 
(Per 
serving
) 
6G 
(Per 
serving) 
8G 
(Per 
serving) 
10G 
(Per 
serving) 
6S 
(Per 
serving) 
10S 
(Per 
serving) 
Twinings Ginger 
& Lemon Tea 
1 teabag 0.15 0.11±0.01 0.01±0.0
0 
0.01±0.0
0 
0.01±0.00 0.01±0.0
0 
Nerada Ginger & 
Lemon Tea 
1 teabag 0.04 0.04±0.00 0.00±0.0
0 
0.00±0.0
0 
0.00±0.00 0.00±0.0
0 
*6G=[6]-gingerol, 8G =[8]-gingerol, 6S=[6]-shogaol, 10G=[10]-gingerol, 10S=[10]-shogaol.  
 
